Sensei Biotherapeutics initiates Phase 1/2 study of SNS-101

Sensei Biotherapeutics (SNSE) announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA. This initial cohort of patients will receive a dose of 3 mg/kg of SNS-101 and a flat dose of Regeneron’s (REGN) PD-1 inhibitor Libtayo at 350 mg. Additionally, the Company announced that the fourth cohort of the monotherapy arm at a dose of 10 mg/kg has been fully enrolled. “We are pleased with the rapid enrollment of our clinical trial and are excited to evaluate SNS-101 as a combination therapy earlier than anticipated,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “Sensei is now treating patients at a dose significantly higher than any VISTA antibody for which clinical data have been reported, while dosing less frequently at a rate of once every three weeks. We believe these important differentiators underscore the vast potential of SNS-101 to treat patients with solid tumors.” As a result of faster enrollment than anticipated, Sensei now expects to report initial combination pharmacokinetic and safety data in Q1 2024 with preliminary anti-tumor activity data in 2024.